Chronic hypertension has been reported to produce adverse cognitive effects in elderly individuals, perhaps by altering central nervous system hemodynamics. The beneficial or adverse effects of antihypertensive drugs on these processes are not well understood. We examined the effects of catopril (90 mglkglday) and propranolol (80 mg/kg/day) on cognitive function and brain blood flow in hypertensive and normotensive rats. Cognitive function was assessed by the Morris water maze, and regional brain blood flow was measured by the [ u C]iodoantipyrine method. Nineteen-month' old propranolol-treated hypertensive rats exhibited poorer performance (p < .05) than control rats and had lower brain blood flows, particularly in white matter regions (p < .01). Captopril-treated hypertensive rats did not differ significantly from control rats with regard to either cognitive performance or brain blood flow. In the normotensive rats, there were no effects of either drug on cognitive performance or brain blood flow. Thus, blood pressure reduction by propranolol but not captopril has an adverse effect on cognitive function and brain blood flow in hypertensive rats.
'T'HERE is considerable evidence that long-standing hy-A pertension is associated with decreased performance on certain cognitive tests, particularly in elderly individuals (Wilkie and Eisdorfer, 1971; Franceschi et al., 1982; Miller et al., 1984; Battersby et al., 1993; Elias et al., 1993; Kuusisto et al., 1993) . The pathophysiologic mechanism of this impaired performance has not been clearly established. Evidence has suggested that various factors may be involved including abnormal cerebral autoregulation (Baumbach et al., 1988) , lacunar infarcts (Matsushitaet al., 1994) , diffuse demyelination (van Swieten et al., 1991) , impaired cerebrovascular reactivity (Tamaki et al., 1995) , decreased local cerebral glucose metabolism (Salerno et al., 1995) , or even insulin resistance (Kuusisto et al., 1993) . Based on these and other observations, it has been hypothesized that chronic hypertension may eventually lead to a reduction in regional cerebral blood flow (rCBF) which could in turn affect cognitive performance . Adequate treatment with antihypertensive drugs would perhaps prevent these adverse effects.
The beneficial or adverse influences of specific antihypertensive drugs on cognitive function in the elderly hypertensive population are not well established. Relatively few studies have been conducted on newer drugs such as the angiotensin-converting enzyme (ACE) inhibitors, whereas a large number of studies have examined the cognitive effects of older drugs such as the (3-blockers (Gengo et al., 1988; Dimsdale et al., 1989; Muldoon et al., 1991; Skinner et al., 1992) . At least two recent reviews have suggested that ACE inhibitors may improve cognitive performance (Domeney, 1994; Marin and Govantes, 1995) . The data on (3-blockers are much less consistent. Most studies have found no effect of p-blockers on cognition, and the few that did were about equally divided between those showing beneficial effects and those showing adverse effects (Dimsdale et al., 1989; Muldoon et al., 1991) .
The subtle nature of these possible drug effects has made them difficult to clarify. Variables such as dosage and duration of exposure may be crucial factors for the presence or absence of detectable drug effects. In addition, a number of confounding factors are often present that can obscure the influence of antihypertensive drugs. A few of the recognized confounding factors include hypertensive disease itself (Wilkie and Eisdorfer, 1971; Franceschi et al., 1982; Batterbsy et al., 1993; Elias et al., 1993) , the aging process (McEntee and Crook, 1990 ), the subject's level of education (Elias et al., 1987) , and concurrent exposure to other drugs (Larson et al., 1986) . In order to minimize and control these complicating factors, this study utilized a hypertensive rat model. We examined the effects of long-term treatment with two common antihypertensive drugs, captopril and propranolol, on cognitive performance and rCBF.
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(Sigma Chemical, St. Louis) and dissolved in drinking water which the animals consumed ad libitum. Drug concentration was adjusted to provide the desired daily dose based on daily drinking records. Drug treatment was continued until the blood flow studies were performed at 19 to 21 months of age. Control animals were given regular tap water. Blood pressure and heart rate were measured indirectly by a tail cuff device (IITC Life Science, Woodland Hills, CA) every 3 months.
Assessment of cognitive function. -Rats were assessed at 2 months of age (baseline, before drug treatment), at 12 months of age, and at 19 months of age. To eliminate possible unrecognized session-to-session confounding factors, the rats were tested in groups which contained both drug-treated and control rats. Cognitive function was evaluated by means of the Morris water maze test. This test has been shown to be a sensitive indicator of spatial memory. It requires intact hippocampal function (Morris et al., 1982) , but performance is dependent on a number of other central processes as well (Morris, 1984) . The Morris water maze has been used extensively to demonstrate the effects of drugs or brain lesions on cognitive performance of rats (Brandeis et al., 1989) .
The apparatus consisted of a circular pool (180 cm diameter by 38 cm height) and a movable plastic platform with a top surface 12 x 12 cm and a height of 23.5 cm. Water level in the pool was maintained at a depth of approximately 2 cm above the top of the platform (i.e., 25.5 cm) and kept at a constant temperature of 29-30 °C. In order to render the platform invisible, the water in the pool was opacified by means of nontoxic black tempra paint (Van Aken, Rancho Cucamonga, CA), and a piece of black carpet was affixed to the top of the platform. The pool environment contained a variety of visual cues that remained unchanged throughout the period of drug administration.
The testing for each animal consisted of 20 swimming trials conducted over a consecutive 2-day period. The goal of each trial was for the rat to swim to the concealed platform. The platform offered the only option for escape from the pool. The first day (acquisition) consisted of eight identical trials in which the platform remained in the center of one of the four pool quadrants. Before the first trial, the rat was placed on the platform for 2 min (familiarization period). The animal was then removed and released from a specific neutral position facing the pool wall opposite from the platform. If the rat mounted the platform within 2 min, it was allowed to rest on the platform for 1 min before the next trial. If not, the trial was scored as a nonarrival and the rat was removed from the pool and placed on the platform for 1 min until the next trial. The second day of testing consisted of eight more swimming trials identical to those on day 1, but were followed immediately by four reversal trials. These reversal trials were performed in a similar manner to the acquisition trials except that the platform was moved to a specific adjacent quadrant without any familiarization period. The reversal trials thus presented a novel learning task to the animals.
Data from the swimming trials were acquired by a video CCD camera (Model JE7542B, Javelin Electronics, Torrance, CA) mounted in the ceiling and analyzed by a computer system. This system consists of a PC 486 computer with an image capture board (Image VGA-CS, Scentech Corp., Woburn, MA) and a Windows-based software program developed by one of the investigators (M.G.). This video tracking system was written in a graphical programming language (LabVIEW for Windows, National Instruments, Austin, TX) using additional image acquisition and analysis tools (Concept V.i, Graftek, Mirmande, France). It can acquire up to 4 frames/sec and extract the position of the rat within the pool of each image. The following measurements were determined on-line: elapsed time to reach the platform (escape latency), total swimming distance, direct distance from the starting point to the platform, swimming speed, number of entries into each of the pool quadrants, and total time spent in each of the pool quadrants. From these measurements the following cognitive parameters were derived and analyzed: search distance (total distance minus the direct distance from the starting position to the platform), escape latency, number of entries into the incorrect (nonplatform) pool quadrants, and total time in the incorrect (nonplatform) pool quadrants. All swimming trials were also recorded on video tape for retrospective or repeat analysis when needed. The swimming speed was analyzed to serve as a psychomotor parameter.
Measurement ofrCBF. -Brain blood flow studies were performed on surviving rats between 19 and 21 months of age. rCBF was measured by the [ 14 C]iodoantipyrine method described by Sakurada et al. (1978) . Rats were anesthetized with methoxyflurane and ketamine. Catheters were surgically implanted in the femoral vein and artery. [ 14 C]iodoantipyrine (American Radiolabeled Chemicals, St. Louis) at a dose of 150 |xCi/kg in 0.7-0.8 ml of normal saline was infused through the femoral vein catheter over a period of 25 sec. Concurrent with the infusion, 9-14 blood samples, approximately 0.1 ml each, were collected into preweighed, filter paper-containing scintillation tubes from the freeflowing arterial catheter.
Immediately at the end of the infusion the rat was decapitated. The brain was removed from the skull within 1 min and frozen by immersion in -40 °C Freon. The brain" was then cut into 20 |xm coronal slices with a cryostat (TissueTek, Miles, Inc., Elkhart, IN) at -17 °C. Every 10th slice was saved for hematoxylin and eosin (H&E) staining. The other slices were laid on glass coverslips and desiccated with a hotplate at 60 °C. The coverslips were then applied face down to x-ray film (X-OMAT AR, Kodak, Rochester, NY) and exposed for 5-7 days.
In order to minimize the statistical effects of multiple comparisons, we chose a priori to survey just five brain regions: parietal cortex, hippocampus, thalamus, corpus callosum, and the internal capsule. We believed that these regions could be measured very reliably and would be both important for cerebral function, as well as offering a representative sampling of anatomically distinct brain regions. The regions of interest (ROI) were identified on the developed film images and verified with the H&E-stained sections. Densities in the ROIs were measured by means of a video camera (Sony AVC-D7) interfaced with a computer digitiz-B456
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ing board (IP-8, Matrox Ltd., Quebec, Canada) and an image analysis program (Image-Pro Plus, Media Cybernetics, Silver Spring, MD). The overall density measurement for each ROI was obtained by averaging the densities at predetermined right and left hemisphere areas of 6-12 brain slices encompassing the anterior to posterior extent of all the ROIs. Thus, the density of an ROI for an individual animal was determined by averaging at least 12 separate measurements.
The densities were converted to tissue radioactivity concentrations (nCi/g) by comparison with commercially available calibration standards (Microscales, Amersham Inc., Arlington Heights, IL) exposed with each set of brain slices. The blood samples were analyzed for radioactivity as follows. After re weighing to determine blood weight, the tubes containing the filter paper samples were mixed with scintillationjiuid (Cryo-Scint, ICN Inc., Irvine, CA) and allowed to stand overnight. The samples were then processed in a scintillation counter (Beckman LS6000TA) to determine nCi per gram of blood.
rCBF was calculated from the formula
where F = the rCBF, C a -arterial blood concentration at each time point, C b = brain tissue concentration at the ROI, \ = the blood-brain partition coefficient for [ 14 C]iodoantipyrine (which has been determined to be 0.8) (Sakurada et al., 1978) , T = total elapsed time from start of infusion to decapitation, and t = elapsed time from start of infusion for each blood sample.
The value of F to the nearest 0.1 ml/g/min was determined for each ROI by successive approximation using the blood and tissue data. Different hypothetical values of F were substituted into the formula along with the blood concentration data. The integral was estimated from the area under the curve using the trapezoidal rule and multiplied by the hypothetical F. The value of F, which resulted in the calculated C b closest to the actual measured C b , was taken as the rCBF for the ROI.
Statistical analysis. -All data were analyzed with a personal computer using the Systat software package (Systat Inc., Evanston, IL). Analysis of variance (ANOVA) for repeated measures was used to assess changes over the entire course of the study. One-way ANOVA with Bonferroni correction was used to compare the three groups at a particular study time point. The Pearson correlation coefficient was used to evaluate associations between variables. Significance was set at/? < .05. Table 1 shows the body weight, water intake, and systolic blood pressure for each group of rats at the end of the study. Differences between the groups were similar at 12 months of age, and there were no significant differences at baseline. Body weights were significantly higher in control SHR and control WKY than for the drug-treated animals. Water intake was significantly lower in propranolol-treated animals of either strain. In the SHR, both drugs lowered blood pressure, but the magnitude of blood pressure lowering was greater with captopril than with propranolol (p < .001). In the WKY, only captopril had a significant hypotensive effect. Heart rates for both SHR and WKY were significantly lower in the propranolol group (p < .001). Heart rate also decreased for captopril-treated SHR, but not for captopriltreated WKY. Two SHR control group rats and one WKY propranolol-treated rat died prior to 19 months of age.
RESULTS
In the SHR, there were no significant performance differences among the three treatment groups at baseline on either the acquisition or the reversal trials (Table 2 and Figure 1A and B). At 12 months, the quadrant times parameter indicated a better performance (p < .021) of the SHR propranolol-treated group on the reversal trials compared to the control group ( Figure IB, asterisk) . No other differences were observed at 12 months. At 19 months, acquisition performance (Table 2 and Figure 1A ) for the SHR propranolol-treated group was significantly worse than the control group in terms of distance (p = .010), quadrant entries (p = .016), and quadrant times (p = .028), and Notes: Values are mean ± standard error; SHR = spontaneously hypertensive; WKY = Wistar-Kyoto.
•Bonferroni-adjustedp-values for control versus captopril (1 vs 2) and control versus propranolol (1 vs 3).
••Control (n = 12), captopril (n = 6), and propranolol (« = 9).
•Control (n = 6), captopril (n = 6), and propranolol (n = 6). nearly significant in terms of latency (p = .050). In contrast, there was no significant SHR acquisition performance difference between captopril and control for any of the parameters (Table 2 and Figure 1A ). In the WKY, there were no significant differences between the two drug-treated groups and the control group at any age on either the acquisition or the reversal trials (Table 2 and Figure 1C and D). There were no treatment-group differences in swimming speeds for either the SHR or the WKY at any age (data not shown). When performance was evaluated by repeated measures analysis across all three testing sessions (baseline, 12 months, and 19 months), there were significant age-bytreatment-group interactions in the SHR (Table 2 and Figure  1 ). On the SHR acquisition trials, this interaction was significant in all four parameters: distance (p -.016), latency (p = .022), quadrant entries (p = .017), and quadrant times (p = .010). On the SHR reversal trials, the age-by-treatment-group interaction was significant for two of the four parameters: quadrant entries (p = .031) and quadrant times (p = .026). There were no age-by-treatmentgroup interactions in the WKY on either the acquisition or the reversal trials (Table 2 and Figure 1) . SHR performance on the acquisition trials remained relatively constant for the control and the captopril groups over the course of the study, but the propranolol group exhibited a significant worsening of performance on the last testing session (p < .05 in all parameters). On the reversal trials, performance of the control group as measured by latency and quadrant times generally deteriorated over the course of the study for the SHR (Table 2 and Figure IB ). An age-related deterioration in performance, similar to that seen in the control SHR, was observed on the control WKY reversal trials (Table 2 and Figure ID) ; all four cognitive parameters tended to worsen with age. Reversal performance worsened between 12 and 19 months for the propranolol-treated SHR (p < .05 in all four parameters) and improved for captopriltreated SHR (p < .05 in all four parameters) during the same interval (Table 2 and Figure IB) . Age alone (without regard to drug treatment) was a significant factor for reversal performance for both the SHR (p = .034) and the WKY (p = .001), but only on the quadrant entries parameter.
Untreated control SHR had a significantly higher mortality (p < .001) than either captopril-or propranolol-treated rats. Two control SHR and one propranolol-treated WKY died prior to 19 months of age (as mentioned above) and five more control SHR died between 19 and 21 months of age before blood flow studies could be carried out. In all cases, the cause of death appeared to be cerebral infarction. To compensate for this survival difference, the SHR control group had to contain a larger number of animals at baseline than did the other groups. Of the surviving rats, successful blood flow studies were carried out on 10 control group (5 SHR and 5 WKY), 8 captopril-treated animals (4 SHR and 4 WKY), and 12 propranolol-treated animals (7 SHR and 5 WKY).
The blood flow results for these animals are shown in Table 3 . The propranolol-treated SHR demonstrated significantly lower blood flow than the control group for all brain regions except the hippocampus. The captopril-treated SHR demonstrated a nonsignificant trend toward lower blood flow than control in all the gray matter regions (cerebral cortex, hippocampus, and the thalamus), but similar blood flow to control in the white matter regions (corpus callosum and the internal capsule). There were too few animals in each group to demonstrate a significant correlation between blood flow and cognitive function. The drug-treated WKY showed no differences from control blood flows in any brain region. There was no significant difference in the performance of rats for which blood flow data were available and those for which no blood flow data were available. as assessed by the quadrant times parameter. (A) SHR performance on the acquisition trials for each of the three treatment groups as measured by the total time spent searching the incorrect quadrants of the pool (quadrant times). *, Significant difference (p < .05) between propranolol and control by Bonferroniadjusted ANOVA. (B) SHR performance on the reversal trials for each of the three treatment groups as measured by the total time spent searching the incorrect quadrants of the pool (quadrant times). *, Significant difference (p < .05) between propranolol and control by Bonferroni-adjusted ANOVA. (C) WKY performance on the acquisition trials for each of the three treatment groups as measured by the total time spent searching the incorrect quadrants of the pool (quadrant times). (D) WKY performance on the reversal trials for each of the three treatment groups as measured by the total time spent searching the incorrect quadrants of the pool (quadrant times). In all cases, higher values indicate poorer performance.
DISCUSSION
To our knowledge, no previous studies have concurrently examined both the cognitive and cerebral hemodynamic effects of lifelong antihypertensive drug treatment. Although both propranolol and captopril lower blood pressure and improve survival in hypertensive rats, this study demonstrates that their effects on cognitive function and brain blood flow are not the same. The significant age-by-treatment-group interactions shown in this study indicate that the selection of a particular antihypertensive drug has an influence on cognitive performance over the animal's lifetime.
Age-related changes in cognitive performance were clearly evident in our results. Age was a significant factor in reversal performance for both WKY and SHR as indicated by the quadrant entries parameter. Thus, aging in either strain was associated with an increase error rate as indicated by this parameter. Overall, WKY and SHR control group reversal performance in particular tended to deteriorate with age. In contrast, performance on the acquisition trials showed little change with age. The acquisition trials reflect a cognitive process requiring spatial learning and memory. The reversal trials involve a more complex process which requires not only learning new spatial information, but also extinction of a previously successful behavior pattern (Morris, 1984) . The different processes involved may help explain the different results for the acquisition and the reversal trials.
Several other studies have examined the effect of aging alone (Gage et al., 1984; Berman et al., 1988; Wree et al., 1991) or aging in hypertensive rats . Generally, these studies all documented significantly impaired performance in the old animals relative to younger animals. The comparison of our results to those obtained in other aging studies is not straightforward. Few, if any, other studies have longitudinally tested the same animals over a 17-month period. The influence of practice effects under these conditions is not known and could be considerably greater than expected. These practice effects may compensate to some degree for age-related deficits in performance. Despite the potential for confounding effects, it could be argued that serial testing of the animals, as in the current study, more closely simulates the human condition than does a paradigm which tests the animals only once in old age.
It is not clear why reversal performance improved at 12 months and worsened at 19 months in the SHR propranololtreated group. A number of human studies have found improved cognitive performance with fJ-blockers (Gengo et al., 1988; Streufert et al., 1988; Skinner et al., 1992) . It is possible that the effect of (3-blockers is age-dependent, and this would help explain the conflicting results in various studies (Dimsdale et al., 1989; Muldoon et al., 1991) . Consistent in both the acquisition and the reversal trials was a significant deterioration in performance between 12 and 19 months in the SHR propranolol-treated group. The fact that swimming speed was not different in any of the treatment groups makes it unlikely that propranolol directly impairs psychomotor function. Our results thus suggest that longterm treatment with propranolol leads to decreased cognitive performance in old SHR, and that this effect is independent of the drug's antihypertensive action. Note: Values are mean ± standard error.
•Bonferroni-adjusted p-values for control versus captopril (1 vs 2) and control versus propranolol (1 vs 3).
•"Control (n = 5), captopril (n = 4), and propranolol (n = 7). 'Control (n = 5), captopril (n = 4), and propranolol (n = 5).
Other studies have examined the behavioral effects of propranolol and captopril in rats. Pretreatment with propranolol had no effect on acquisition or retention in SpragueDawley rats trained with a brief footshock (Gold et al., 1986) . Similarly, spatial working memory in rats was not affected by propranolol pretreatment (Beatty and Rush, 1983; Kobayashi et al., 1995) . Place learning in rats, as assessed by Morris water maze, was not affected by administration of propranolol alone, but was impaired when propranolol was coadministered with scopolamine (Decker et al., 1990) . Evidence from animal studies suggests that ACE inhibitors may have cognitive-enhancing effects. Captopril was found to block the deficits in spatial memory produced by trimethylin injection in rats (Earley et al., 1989) . In mice, captopril has been shown to reduce the amnesiogenic effects of cerebral electroshock treatment (Mondadori and Etienne, 1990) and improve basal performance in a habituation model (Barnes et al., 1992) . None of these studies used hypertensive animals. In the current study we found that captopril improved SHR reversal performance between 12 and 19 months of age.
The blood flow results must be interpreted with caution because of the disproportionate mortality in the SHR control group and small number of animals successfully studied in each group. Nevertheless, the SHR control and propranololtreated groups exhibited dramatic differences in blood flow to the white matter regions of the corpus callosum and internal capsule. Recent studies have shown that elderly hypertensive patients have white matter lesions and cognitive impairment (van Swieten et al., 1991; Matsushita et al., 1994) . Hypertension is also associated with impaired cerebral autoregulation and decreased glucose metabolism in subcortical brain regions (Matsushita et al., 1994; Salerno et al., 1995) . Several animal studies have also shown that chronic hypertension is associated with decreased glucose metabolism in various brain regions (Gage et al., 1984; Wree et al., 1991; Wei et al., 1992) . The current study was not designed to evaluate the effect of age or chronic hypertension on regional brain blood flow since comparative blood flow studies were not performed on young animals. Others have found an inconsistent relationship between age and brain blood flow (Berman et al., 1988; Wei et al., 1992; Tamakietal., 1995) .
Addition of the antihypertensive drugs to drinking water may have rendered it distasteful to the rats, resulting in decreased water intake. This effect in turn may have decreased salivation and led to decreased food intake and decreased body weight. However, previous studies have suggested that ACE inhibitors administered intracerebroventricularly also decrease water intake, perhaps by an effect on central nervous system converting enzyme (Saad et al., 1992) . Decreased food intake and body weight may be partially responsible for the increased longevity of the drugtreated animals. The drug doses used in this study were similar to those used in other studies to produce an antihypertensive effect in SHR (Gries et al., 1989; Kuzuo et al., 1993) . The magnitude of blood pressure lowering was less for propranolol than for captopril. Although it would-have been ideal to administer larger doses of propranolol and achieve an antihypertensive effect similar to that produced by captopril, it was not possible to maintain adequate fluid intake with higher concentrations of propranolol in the drinking water. However, the significantly decreased heart rate in the propranolol-treated rats indicates that therapeutic drug levels were achieved in the propranolol-treated group.
In conclusion, we found that lifetime treatment with propranolol resulted in impaired cognitive performance and decreased regional brain blood flow in hypertensive rats. Additional studies are needed to determine the possible clinical significance of these results and whether regional brain blood flow directly correlates with performance. Propranolol is much less commonly used to treat hypertension in this country today than it was in the past. It remains to be seen whether the newer, more selective, and less lipid soluble fJ-blockers would produce the same results as propranolol. Also unclear is the length of drug exposure re-
